Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free LABS Stock Alerts

MediPharm Labs (LABS) Competitors

MediPharm Labs logo
C$0.08 +0.01 (+7.14%)
As of 09/23/2026 03:09 PM Eastern
Compare

LABS vs. MGW, I, TGOD, NINE, and IGX

Should you buy MediPharm Labs stock or one of its competitors? MediPharm Labs's main competitors and comparable companies include Maple Leaf Green World (MGW), Intellipharmaceutics International (I), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), and IntelGenx Technologies (IGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediPharm Labs compare to Maple Leaf Green World?

MediPharm Labs (TSE:LABS) and Maple Leaf Green World (CVE:MGW) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Maple Leaf Green World has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Maple Leaf Green World's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-12.00% -13.79% -7.17%
Maple Leaf Green World N/A N/A N/A

Maple Leaf Green World has lower revenue, but higher earnings than MediPharm Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A
Maple Leaf Green WorldN/AN/AN/AN/AN/A

0.3% of MediPharm Labs shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MediPharm Labs' average media sentiment score of 0.00 equaled Maple Leaf Green World'saverage media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
Maple Leaf Green World Neutral

Summary

MediPharm Labs and Maple Leaf Green World tied by winning 3 of the 6 factors compared between the two stocks.

How does MediPharm Labs compare to Intellipharmaceutics International?

Intellipharmaceutics International (TSE:I) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Intellipharmaceutics International's average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Intellipharmaceutics International Neutral
MediPharm Labs Neutral

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Intellipharmaceutics International has higher earnings, but lower revenue than MediPharm Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics InternationalN/AN/AN/AN/AN/A
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

Intellipharmaceutics International has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Intellipharmaceutics International's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellipharmaceutics InternationalN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

Summary

Intellipharmaceutics International and MediPharm Labs tied by winning 3 of the 6 factors compared between the two stocks.

How does MediPharm Labs compare to Green Organic Dutchman?

Green Organic Dutchman (TSE:TGOD) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Green Organic Dutchman's average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Green Organic Dutchman Neutral
MediPharm Labs Neutral

MediPharm Labs has higher revenue and earnings than Green Organic Dutchman. MediPharm Labs is trading at a lower price-to-earnings ratio than Green Organic Dutchman, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Green Organic DutchmanC$31.37M0.00-C$137.58M-C$0.26N/A
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Green Organic Dutchman has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Green Organic Dutchman's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Green Organic DutchmanN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

Summary

MediPharm Labs beats Green Organic Dutchman on 5 of the 9 factors compared between the two stocks.

How does MediPharm Labs compare to Delta 9 Cannabis?

Delta 9 Cannabis (CVE:NINE) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

0.3% of MediPharm Labs shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Delta 9 Cannabis' average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Delta 9 Cannabis Neutral
MediPharm Labs Neutral

Delta 9 Cannabis has higher earnings, but lower revenue than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$12.87M6.94C$4.69MC$0.0519.07
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

Delta 9 Cannabis has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Delta 9 Cannabis' return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Delta 9 CannabisN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

Summary

Delta 9 Cannabis beats MediPharm Labs on 7 of the 10 factors compared between the two stocks.

How does MediPharm Labs compare to IntelGenx Technologies?

IntelGenx Technologies (CVE:IGX) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, IntelGenx Technologies' average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
IntelGenx Technologies Neutral
MediPharm Labs Neutral

0.3% of MediPharm Labs shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IntelGenx Technologies has higher earnings, but lower revenue than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

IntelGenx Technologies has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. IntelGenx Technologies' return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
IntelGenx TechnologiesN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

Summary

IntelGenx Technologies beats MediPharm Labs on 6 of the 10 factors compared between the two stocks.

Get MediPharm Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABS vs. The Competition

Export
MetricMediPharm LabsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$29.90MC$12.60BC$7.31BC$12.84B
Dividend YieldN/A2.63%2.52%6.27%
P/E Ratio-7.50792.28274.0840.36
Price / Sales0.77862.22638.219.35
Price / Cash1.3088.6477.8082.29
Price / Book0.9010.5910.474.69
Net Income-C$12.05MC$2.81BC$3.49BC$299.09M
7 Day PerformanceN/A-0.11%-0.67%0.01%
1 Month PerformanceN/A-1.34%-3.17%-2.14%
1 Year PerformanceN/A2.86%15.14%20.17%

MediPharm Labs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABS
MediPharm Labs
N/AC$0.08
+7.1%		N/A+7.1%C$29.90MC$41.46MN/A130
MGW
Maple Leaf Green World
N/AC$0.79
+777.8%		N/A+0.0%C$111.69MN/AN/AN/A
I
Intellipharmaceutics International
N/AN/AN/AN/AC$97.40MN/AN/A1,069
TGOD
Green Organic Dutchman
N/AN/AN/AN/AC$89.95MC$31.37MN/A41
NINE
Delta 9 Cannabis
N/AC$1.03
+3.0%		N/A+0.0%C$89.36MC$12.87M19.07940

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:LABS) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel